Shattuck Labs' oncology segment is dedicated to the discovery and development of novel therapies for the treatment of various cancers. This involves extensive research and development activities focused on bi-functional fusion proteins designed to modulate the immune system and directly target tumor cells. Key technologies include the ARC (Agonist Redirected Checkpoint) platform, which aims to enhance anti-tumor immunity. Clinical trials are underway for lead product candidate SL-172154, targeting ovarian, fallopian tube, and peritoneal cancers. The segment addresses significant unmet needs in cancer treatment, seeking to improve patient outcomes and survival rates. Future opportunities include expanding the pipeline with new ARC-based therapies and exploring combination strategies with existing cancer treatments. Regulatory compliance and clinical validation are critical aspects of this segment.

This segment focuses on developing innovative treatments for autoimmune and inflammatory diseases. Shattuck Labs leverages its ARC platform to create bi-functional fusion proteins that can rebalance the immune system and resolve chronic inflammation. Research and development efforts are directed towards identifying novel targets and designing therapies that selectively modulate immune responses. A key collaboration with Ono Pharmaceutical aims to generate new bifunctional fusion proteins for autoimmune and inflammatory conditions. The segment addresses a broad range of diseases, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis, with the goal of providing more effective and targeted treatments. Future growth potential lies in expanding partnerships and advancing promising preclinical candidates into clinical development. Regulatory pathways and clinical efficacy are key considerations for this segment.